In Brief: Anika Therapeutics/Zimmer
This article was originally published in The Gray Sheet
Executive Summary
Anika Therapeutics/Zimmer: Firms ink agreement whereby Bristol-Myers Squibb's Zimmer unit gains exclusive marketing and distribution rights in the U.S., Canada and "select Asia-Pacific markets" to Anika's Orthovisc intra-articular hyaluronic acid injection for treatment of osteoarthritis of the knee, Anika says. Zimmer will make an upfront payment of $2.5 mil.; additional milestone payments to Anika could total $20.5 mil. The two companies will split revenues generated from sales of the product, for which Anika expects to submit a premarket approval application to FDA by the end of the year ("The Gray Sheet" Oct. 6, In Brief)...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.